Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin in amyotrophic lateral sclerosis
ISRCTN38393880Phase 2Completed
- Sponsor
- Instituto Cardiológico Banfield
- Start
- Jul 2021
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in amyotrophic lateral sclerosis (ALS) comparing Cerebrolysin + riluzole with Placebo + riluzole (2 arms). Primary endpoint: ALSFRS-R change from baseline to month 1. Started Jul 2021; status: completed.
02
Drugs
cerebrolysin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ISRCTN38393880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38393880.